Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome

NCT02610543 is registered in ClinicalTrials.gov with UCB Celltech as lead sponsor.

NCT NCT02610543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02610543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome
Lead sponsor
UCB Celltech
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2015
Completion date
December 5, 2017
Enrollment
27 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome